DHR:NYE-Danaher Corporation (USD)

EQUITY | Diagnostics & Research | New York Stock Exchange

Last Closing

USD 204.53

Change

-1.77 (-0.86)%

Market Cap

USD 54.15B

Volume

5.59M

Analyst Target

USD 220.40
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Danaher Corp designs, manufactures & markets professional, medical, industrial & commercial products.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-02-18 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap
A Agilent Technologies Inc

+1.95 (+1.44%)

USD 43.23B
IQV IQVIA Holdings Inc

+3.36 (+1.74%)

USD 36.97B
LH Laboratory Corporation of Amer..

+1.53 (+0.62%)

USD 20.54B
DGX Quest Diagnostics Incorporated

+2.10 (+1.24%)

USD 18.67B
QGEN Qiagen NV

-0.79 (-1.97%)

USD 9.65B
CRL Charles River Laboratories

+10.61 (+6.87%)

USD 8.50B
VNRX Volitionrx Ltd

N/A

USD 0.06B
ENZ Enzo Biochem Inc

+0.02 (+3.29%)

USD 0.03B
TMO Thermo Fisher Scientific Inc

+7.77 (+1.49%)

N/A
MTD Mettler-Toledo International I..

+29.75 (+2.34%)

N/A

ETFs Containing DHR

AILG 6.99 % 0.00 %

N/A

N/A
SYNB Putnam Biorevolution ETF 6.25 % 0.00 %

-0.12 (0.04%)

USD 5.39M
DXSF:XETRA 5.91 % 0.00 %

N/A

N/A
LIFE-U:CA Evolve Global Healthcare .. 5.53 % 0.00 %

N/A

N/A
ZWHC:CA BMO Covered Call Health C.. 4.69 % 0.00 %

+0.34 (+0.04%)

N/A
XDG3:XETRA 4.49 % 0.00 %

N/A

N/A
XGEN:XETRA 4.34 % 0.00 %

N/A

N/A
WHCS:SW iShares MSCI World Health.. 4.21 % 0.00 %

N/A

N/A
YALL God Bless America ETF 4.17 % 0.00 %

+0.10 (+0.04%)

N/A
XGES:LSE Xtrackers MSCI Genomic He.. 4.11 % 0.00 %

+0.20 (+0.04%)

N/A
CBUF:F 4.06 % 0.00 %

N/A

N/A
BWTG Brendan Wood TopGun ETF 4.04 % 0.00 %

+0.07 (+0.04%)

USD 0.01B
SANE 3.95 % 0.00 %

N/A

N/A
BCHP EGSHARES BLUE CHIP ETF EG.. 3.70 % 0.00 %

+0.08 (+0.04%)

USD 0.10B
LS:CA 3.17 % 2.21 %

N/A

N/A
XUHC:SW 3.16 % 0.00 %

N/A

N/A
IUHC:SW iShares S&P 500 Health Ca.. 3.06 % 0.00 %

+0.09 (+0.04%)

N/A
GXLV:LSE SPDR® S&P® U.S. Health .. 3.06 % 0.00 %

+0.43 (+0.04%)

N/A
ZPDH:F 2.93 % 0.00 %

N/A

N/A
SXLV:SW SPDR S&P U.S. Health Care.. 2.93 % 0.00 %

N/A

N/A
XUHC:F 2.85 % 0.00 %

N/A

N/A
CNEQ The Alger ETF Trust 2.83 % 0.00 %

-0.13 (0.04%)

N/A
INNO 2.76 % 0.00 %

N/A

N/A
USRI:LSE 2.50 % 0.00 %

N/A

N/A
BKDV BNY Mellon ETF Trust II 2.45 % 0.00 %

+0.01 (+0.04%)

USD 0.02B
UPVLD:SW 2.35 % 0.00 %

N/A

N/A
ASRP:XETRA 2.30 % 0.00 %

N/A

N/A
XMLH:F 1.94 % 0.00 %

N/A

N/A
DOCT:SW L&G Healthcare Breakthrou.. 1.94 % 0.00 %

+0.09 (+0.04%)

USD 0.07B
USRI:PA AMUNDI MSCI USA SRI Clima.. 1.92 % 0.00 %

+0.84 (+0.04%)

USD 1.20B
WEBD:XETRA 1.92 % 0.00 %

N/A

N/A
XAMB:F 1.53 % 0.00 %

N/A

N/A
HYLG Global X Funds - Global X.. 1.44 % 0.00 %

N/A

N/A
LESW:LSE 1.38 % 0.00 %

N/A

N/A
WSRI:LSE 1.30 % 0.00 %

N/A

N/A
WELB:XETRA 1.08 % 0.00 %

N/A

N/A
RAVI FlexShares Ready Access V.. 0.86 % 0.25 %

+0.01 (+0.04%)

USD 1.22B
CWW.A:CA 0.00 % 1.49 %

N/A

N/A
IXJ iShares Global Healthcare.. 0.00 % 0.46 %

+0.66 (+0.04%)

N/A
IYH iShares U.S. Healthcare E.. 0.00 % 0.43 %

+0.75 (+0.04%)

N/A
JHMH 0.00 % 0.46 %

N/A

N/A
JMIN 0.00 % 0.12 %

N/A

N/A
EVSTC 0.00 % 0.00 %

N/A

N/A
HIG:CA Global Healthcare Income .. 0.00 % 1.02 %

+0.05 (+0.04%)

CAD 0.05B
FHI:CA CI Health Care Giants Cov.. 0.00 % 0.75 %

+0.12 (+0.04%)

CAD 0.10B
HWF:CA 0.00 % 0.00 %

N/A

N/A
HHL-U:CA Harvest Healthcare Leader.. 0.00 % 0.00 %

+0.03 (+0.04%)

N/A
FHI-B:CA CI Health Care Giants Cov.. 0.00 % 0.00 %

-0.17 (0.04%)

CAD 0.05B
RXL ProShares Ultra Health Ca.. 0.00 % 0.95 %

+1.21 (+0.04%)

N/A
VHT Vanguard Health Care Inde.. 0.00 % 0.10 %

+3.18 (+0.04%)

N/A
MIVG:CA Mackenzie Ivy Global Equi.. 0.00 % 0.89 %

+0.23 (+0.04%)

CAD 0.02B
IHCU:LSE iShares S&P 500 Health Ca.. 0.00 % 0.00 %

+10.00 (+0.04%)

N/A
SXLV:LSE SPDR S&P U.S. Health Care.. 0.00 % 0.00 %

+0.39 (+0.04%)

N/A
XDWH:LSE Xtrackers MSCI World Heal.. 0.00 % 0.00 %

+0.24 (+0.04%)

N/A
EMWE:F 0.00 % 0.00 %

N/A

N/A
GNAR:F 0.00 % 0.00 %

N/A

N/A
QDVG:F 0.00 % 0.00 %

N/A

N/A
EWRD:XETRA 0.00 % 0.00 %

N/A

N/A
GNAR:XETRA 0.00 % 0.00 %

N/A

N/A
QDVG:XETRA 0.00 % 0.00 %

N/A

N/A
VMOM:XETRA 0.00 % 0.00 %

N/A

N/A
XUHC:XETRA 0.00 % 0.00 %

N/A

N/A
ZPDH:XETRA 0.00 % 0.00 %

N/A

N/A
NUSA:CA NBI Active U.S. Equity ET.. 0.00 % 0.00 %

+0.47 (+0.04%)

CAD 0.07B
XMLH:XETRA 0.00 % 0.00 %

N/A

N/A
XOUT GraniteShares XOUT U.S. L.. 0.00 % 0.00 %

N/A

N/A
HHL-B:CA Harvest Healthcare Leader.. 0.00 % 0.00 %

+0.12 (+0.04%)

N/A
MEDTE:PA BNP Paribas Easy ECPI Glo.. 0.00 % 0.00 %

+0.01 (+0.04%)

N/A
MTUSD:PA BNP Paribas Easy ECPI Glo.. 0.00 % 0.00 %

-0.01 (0.04%)

N/A

Market Performance

  Market Performance vs. Industry/Classification (Diagnostics & Research) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -10.90% 31% F 6% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return -10.90% 23% F 6% D-
Trailing 12 Months  
Capital Gain -17.45% 38% F 12% F
Dividend Return 0.44% 43% F 4% F
Total Return -17.02% 38% F 11% F
Trailing 5 Years  
Capital Gain 43.96% 50% F 70% C-
Dividend Return 3.05% 40% F 8% B-
Total Return 47.01% 50% F 65% D
Average Annual (5 Year Horizon)  
Capital Gain 6.39% 46% F 55% F
Dividend Return 6.77% 46% F 49% F
Total Return 0.38% 43% F 10% F
Risk Return Profile  
Volatility (Standard Deviation) 28.56% 54% F 37% F
Risk Adjusted Return 23.69% 38% F 38% F
Market Capitalization 54.15B 100% F 99% N/A

Key Financial Ratios

  Ratio vs. Industry/Classification (Diagnostics & Research) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 22.10 38% 16%
Price/Book Ratio 3.00 44% 30%
Price / Cash Flow Ratio 22.23 22% 15%
Price/Free Cash Flow Ratio 22.35 33% 15%
Management Effectiveness  
Return on Equity 7.59% 56% 51%
Return on Invested Capital 11.45% 56% 70%
Return on Assets 3.86% 33% 65%
Debt to Equity Ratio N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

Superior Dividend Growth

This stock has shown top quartile dividend growth in the previous 5 years compared to its sector

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.